Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions.
In 2025, industry layoffs continued to rise year over year, prompting the need for another edition of this article.
As always, please reach out to the Fierce Biotech editorial team with any news of a biopharma workforce reduction. We are committed to protecting the anonymity of all tips, but we do conduct further reviews to verify all information we receive.
Editor's note about the numbers: Layoff rounds that are part of a company's larger, already-announced reorganization are not included in the monthly total count.
January—2 companies
Jan. 8 - Tessera Therapeutics: The Flagship-founded company is planning to lay off 90 employees across a number of states starting March 8. The Massachusetts-based biotech isn’t expecting to close any of its facilities in connection with the layoffs. Story
Jan. 2 - Nido Biosciences: After its lead neurological disease candidate disappointed in a midstage study, the neurobiotech is closing its doors. “Just a handful of employees” will be impacted, a Nido spokesperson told Fierce. Story